Indefinite Delivery Contract SPE2DX16D9415

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, under the SPE2DB program. The IDC, valued at $499,999,999 and valid through November 2026, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

Through this IDC and associated delivery orders, DMS Pharmaceutical Group Inc. is positioned as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of a diverse array of pharmaceutical items and pharmacy services to Department of Defense healthcare sites. The delivery orders, which are not associated with any set-aside designations, cover a wide range of medical needs, including oncology treatments, contraceptives, auto-injectors, and specialized pharmaceutical products. This contract allows DMS Pharmaceutical Group Inc. to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains.